Compounded Tirzepatide vs Zepbound and Mounjaro

The history is short. Tirzepatide went onto the FDA shortage list in December 2022, and the shortage allowed pharmacies to compound it at scale. The FDA declared the shortage resolved in December 2024 — earlier than semaglutide's — and by spring 2025 the enforcement grace periods for compounders had run out. Lilly followed with litigation against compounders and telehealth sellers it considered to be marketing copies.

Then in April 2026 the FDA proposed excluding tirzepatide, along with semaglutide and liraglutide, from the 503B bulks list altogether — the finding being that there is no clinical need for outsourcing facilities to compound it from bulk ingredient. Public comment closed at the end of June 2026.

What survives all of that is narrow but real: a 503A pharmacy may still compound tirzepatide for a named patient on a valid prescription, where the formulation differs from the approved product for a documented clinical reason. What does not survive is the version of the industry that sold a straightforward copy at a discount.

Two things, both worth having in mind when you evaluate a provider.

The salt-form problem is smaller. The FDA's warnings about compounders using semaglutide sodium or acetate — salt forms that are not the approved active ingredient — were specific to semaglutide. Tirzepatide has not had an equivalent flood of wrong-form product. Ask anyway; the answer should be "tirzepatide base."

The approved vial exists. Because Lilly sells Zepbound vials outside insurance, the usual justification for a compounded product — "the approved drug is unaffordable or unavailable" — has to clear a higher bar for tirzepatide than for most compounded drugs. A provider prescribing compounded tirzepatide should be able to tell you why, in your case, the approved vial is not the answer.

They are the same three as for any compounded GLP-1. Which pharmacy will fill it and whether it is licensed in your state — an answer you are entitled to before you pay, and one that is printed on the label regardless. Which form of the molecule. What batch testing stands behind the lot you are receiving, and how to obtain it.

And a fourth, specific to tirzepatide: why not the approved vial? There can be good answers. There should be an answer.

Tirzepatide at ACT 2 is prescribed as a clinical decision, and the route it reaches you by depends on your coverage and your circumstances. Where Zepbound or Mounjaro is covered, that is usually the route, and the Weight Loss Program Membership provides the supervision around it. Where a compounded product is prescribed, it is filled by a state-licensed compounding pharmacy in our platform's network, as tirzepatide base, and shipped directly to you. We do not publish the pharmacy's name here; your clinician will tell you which pharmacy will dispense your prescription, that it is licensed in your state, why the compounded product rather than the approved vial in your case, and how to obtain batch documentation for your lot — before you fill, and in writing if you ask. The pharmacy is named on the label of everything you receive.

We do not compete on price, and we will not tell you that compounded tirzepatide is equivalent to Zepbound. The trials were run with the approved product. A compounded version borrows that evidence to exactly the extent the pharmacy behind it deserves.